Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 1,000 shares at $234.87 ($233K) on 2014-10-01, disclosed to the SEC on 2014-10-03.
Scheduled sale ($233k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $232.92 | 900 | $210K | 89.9% |
| 2 | $234.87 | 100 | $23K | 10.1% |
| Total | $233.12 avg | 1,000 | $233K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |